NCT07141004招募中4 期
A Phase-IV, Multicenter, Non-Comparative, Open-Label Study Evaluating the Safety and Efficacy of Guselkumab Administered Subcutaneously in the Treatment of Indian Patients With Psoriatic Arthritis
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 100
- 试验地点
- 14
- 主要终点
- Number of Participants With Adverse Events (AEs)
研究概览
简要总结
The purpose of this study is to evaluate the safety and how well guselkumab treatment works (efficacy) in participants with psoriatic arthritis (PsA; a chronic, autoimmune form of arthritis that causes joint inflammation) who had inadequate response to standard therapies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants who have definite diagnosis of active psoriatic arthritis (PsA) (according to the ClASsification criteria for Psoriatic Arthritis [CASPAR]) prior to the first administration of study drug and have at least 1 of the PsA subsets: distal interphalangeal joint arthritis, polyarticular arthritis with the absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis
- •Participants who are negative for rheumatoid factors
- •Participants having inadequate response (defined by presence of active arthritis [presence of any swollen or any tender joint]) to standard therapies for 3 months at the highest recommended dose (e.g., conventional disease-modifying antirheumatic drugs [DMARDs] including methotrexate, apremilast, or nonsteroidal anti-inflammatory drugs [NSAIDs]), including biologics naïve patient or have failed, or were intolerant to one or more biological treatments [anti-TNF/IL-17i]
- •Participants are considered eligible per the following Tuberculosis (TB) screening criteria:
- •Have no history of TB prior to screening AND
- •Have no signs or symptoms suggestive of active TB upon medical history and/or physical examination AND
- •Have had no recent close contact with a person with active TB, or if there has been such contact, will be referred to a physician specializing in TB to undergo additional evaluation and, if warranted, receive appropriate treatment for latent TB prior to or simultaneously with the first administration of study drug AND
- •Within 6 weeks prior to the first administration of study drug, have a negative QuantiFERON- TB Gold and a negative tuberculin skin test result, OR have a newly identified positive QuantiFERON-TB Gold or tuberculin skin test result during screening in which active TB has been ruled out and for which appropriate treatment for latent TB has been initiated either prior to or simultaneously with the first administration of study drug AND
- •Have a chest radiograph (both posterior-anterior and lateral views), taken within 3 months prior to the first administration of study drug and read by a qualified radiologist, with no evidence of current active TB or old inactive TB
- •Medically stable on the basis of physical examination, medical history, vital signs, and 12-lead ECG
- •A woman of childbearing potential must have a negative highly sensitive serum beta-hCG at screening visit
排除标准
- •History of latent or active granulomatous infection prior to screening
- •Have a known clinically significant hypersensitivity to guselkumab or to any of the excipients
- •Have had a serious infection, or have been hospitalized for an infection, or have been treated with intravenous (IV) antibiotics for an infection within 2 months prior to first administration of study intervention
- •Has any known malignancy or has a history of malignancy, or a history of lymphoproliferative disease
- •Have received, or are expected to receive, any live virus or bacterial vaccination within 3 months before the first administration of study intervention, during the study, or within 6 months after the last administration of study intervention
研究组 & 干预措施
Guselkumab
Experimental
Participants will receive subcutaneous injections of guselkumab at Weeks 0, 4, 12, and 20.
干预措施: Guselkumab (Drug)
结局指标
主要结局
Number of Participants With Adverse Events (AEs)
时间窗: Up to 32 weeks
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
Number of Participants With Serious Adverse Events (SAEs)
时间窗: Up to 32 weeks
A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important.
次要结局
- Percentage of Participants Who Achieve an American College of Rheumatology (ACR) 20 Response at Week 12(Week 12)
- Percentage of Participants Who Achieve an ACR 20 Response at Week 24(Week 24)
- Change From Baseline in Analytic Marker of Inflammation (CRP Levels) at Weeks 12 and 24(Baseline, Weeks 12 and 24)
研究者
研究点 (14)
Loading locations...
相似试验
已完成
4 期
A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque PsoriasisPsoriasisNCT04914429Janssen Research & Development, LLC327
已完成
2 期
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)Psoriatic ArthritisNCT02319759Janssen Research & Development, LLC149
已完成
3 期
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)Arthritis, PsoriaticNCT03162796Janssen Research & Development, LLC383
已完成
3 期
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic ArthritisArthritis, PsoriaticNCT03158285Janssen Research & Development, LLC741
进行中（未招募）
4 期
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial DiseaseArthritis, PsoriaticNCT04929210Janssen Research & Development, LLC411